Trastuzumab-Conjugated Liposome-Coated Fluorescent Magnetic Nanoparticles to Target Breast Cancer.
10.3348/kjr.2014.15.4.411
- Author:
Mijung JANG
1
;
Young Il YOON
;
Yong Soo KWON
;
Tae Jong YOON
;
Hak Jong LEE
;
Sung Il HWANG
;
Bo La YUN
;
Sun Mi KIM
Author Information
1. Department of Radiology, Seoul National University Bundang Hospital, Seongnam 463-707, Korea. kimsmlms@daum.net
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Breast cancer;
Drug delivery;
Iron oxide nanoparticles;
Magnetic resonance imaging;
Trastuzumab
- MeSH:
3T3 Cells;
Animals;
Antibodies, Monoclonal, Humanized/*administration & dosage;
Antineoplastic Agents/*administration & dosage;
Breast Neoplasms/chemistry/*drug therapy;
Cell Line, Tumor;
Drug Delivery Systems/methods;
Female;
Ferric Compounds/chemistry;
Humans;
Liposomes;
Magnetite Nanoparticles/administration & dosage/*chemistry;
Mice;
Molecular Targeted Therapy/methods;
Nanoconjugates/administration & dosage/*chemistry;
Nanoparticles/chemistry;
*Receptor, erbB-2/immunology;
Silicon Dioxide/administration & dosage/*chemical synthesis/chemistry
- From:Korean Journal of Radiology
2014;15(4):411-422
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To synthesize mesoporous silica-core-shell magnetic nanoparticles (MNPs) encapsulated by liposomes (Lipo [MNP@m-SiO2]) in order to enhance their stability, allow them to be used in any buffer solution, and to produce trastuzumab-conjugated (Lipo[MNP@m-SiO2]-Her2Ab) nanoparticles to be utilized in vitro for the targeting of breast cancer. MATERIALS AND METHODS: The physiochemical characteristics of Lipo[MNP@m-SiO2] were assessed in terms of size, morphological features, and in vitro safety. The multimodal imaging properties of the organic dye incorporated into Lipo[MNP@m-SiO2] were assessed with both in vitro fluorescence and MR imaging. The specific targeting ability of trastuzumab (Her2/neu antibody, Herceptin(R))-conjugated Lipo[MNP@m-SiO2] for Her2/neu-positive breast cancer cells was also evaluated with fluorescence and MR imaging. RESULTS: We obtained uniformly-sized and evenly distributed Lipo[MNP@m-SiO2] that demonstrated biological stability, while not disrupting cell viability. Her2/neu-positive breast cancer cell targeting by trastuzumab-conjugated Lipo[MNP@m-SiO2] was observed by in vitro fluorescence and MR imaging. CONCLUSION: Trastuzumab-conjugated Lipo[MNP@m-SiO2] is a potential treatment tool for targeted drug delivery in Her2/neu-positive breast cancer.
